| Company Name: | Genta, Incorporated | | Ticker Symbol: | GETA | | | WWW Address: | www.genta.com | | CEO: | Dr. Raymond P. Warrell, Jr., M.D. | | No. of Employees: | 25 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is engaged in pharmaceutical, or drug, research and development.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.151 |  -0.0115 | 0.15 | 0.155 | 0.161 | 0.18 | 0.16 | 4450330 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 29.5 | 181.7 | -0.97 | -455.00 | 0.00 | 0.0 | 0.0 | 17.00 - 0.09 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.16 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 29.5 | mil |
| Latest Shares Outstanding | 181.7 | mil |
| Earnings pS (EPS) | -455.00 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 14,520 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 127.0 | mil |
| Float as % of Shares Outstanding | 95.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 8,292.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 8,717.20 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -238.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -658.0 | % |
| Current Ratio | 0.7 | |
| Leverage Ratio (Assets/Equity) | 5.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 1.33 | |
| LT Debt/Total Capital | 49.0 | % |
| Working Capital pS | -0.02 | $ |
| Cash pS | 0.04 | $ |
| Book-Value pS | 0.02 | $ |
| Tangible Book-Value pS | 0.02 | $ |
| Cash Flow pS | -0.15 | $ |
| Free Cash Flow pS | -0.10 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 8.45 | |
| Price/Tangible Book Ratio | 8.45 | |
| Price/Cash Flow | -1.1 | |
| Price/Free Cash Flow | -1.6 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.3 | 95 | 38,400 | 28,265 |
| 4 Weeks | 0.24 | 0.16 | 0.22 | -27.5 | 68 | 41,863 | 669,805 |
| 13 Weeks | 1.26 | 0.11 | 0.38 | -57.5 | 40 | 53,965 | 3,237,921 |
| 26 Weeks | 1.26 | 0.11 | 0.60 | -72.7 | 23 | 38,339 | 4,754,026 |
| 52 Weeks | 17.00 | 0.09 | 15.50 | -99.0 | 1 | 32,142 | 7,971,174 |
| YTD | 1.55 | 0.11 | - | 20.4 | 98 | 34,416 | 7,778,054 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.17 | 0.19 | 0.60 | 0.50 | 0.48 | -0.97 | -1.05 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -60.69 | 78.0 | -32.18 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -46.51 | NA | 38.55 |
| R&D | -22.78 | NA | -10.98 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -50.4 | -57.4 | -37.4 |
| Earnings % | 0.0 | -100.0 | 0.0 |
| EPS % | 0.0 | -100.0 | 0.0 |
| EPS $ | 747.52 | -5.15 | -415.50 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -41.13 |
| Current Ratio | 0.5 |
| Quick Ratio (Acid Test) | 0.4 |
| Liquidity Ratio (Cash) | 0.44 |
| Receivables Turnover | 22.0 |
| Average Collection Period | 16 |
| Working Capital/Equity | 107.3 |
| Working Capital pS | -0.54 |
| Cash-Flow pS | -51.95 |
| Free Cash-Flow pS | -2.65 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -186.85 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 138.3 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 431.1 |
| LT Debt/Total Liabilities | 36.1 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 116.95 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.53 |
| Tobin's Q Ratio | 2.33 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -1.40 |
| Enterprise Value (EV)/Free Cash Flow | -0.97 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 8.45 |
| Price/Book Ratio - LTM | 8.45 |
| Price/Cash Flow Ratio | -1.1 |
| Price/Free Cash Flow Ratio - LTM | -1.6 |
| Price/Sales Ratio | 164.01 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.65 |
| Current Liabilities pS | 1.15 |
| Tangible Book Value pS - LTM | 0.02 |
| Book Value pS - LTM | 0.02 |
| Capital Invested pS | 0.01 |
| Cash pS - LTM | 0.04 |
| Cash Flow pS - LTM | -0.15 |
| Free Cash Flow pS - LTM | -0.10 |
| Earnings pS (EPS) | -455.00 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -7,106.34 |
| Free Cash Flow Margin 5YEAR AVG | -3,903.16 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.07 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.25 |
| Return on Capital Invested (ROCI) | -34434.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -1701.3 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -3985.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | -361.6 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 13.9 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.4 |
| Effective Tax Rate - 5YEAR AVRG. | 5.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | -1,196 |
| Revenue per Employee | 14,520 |
| Net Income per Employee | -20,233,520 |
| Average Collection Period | 2 |
| Receivables Turnover | 22.0 |
| Day's Inventory Turnover Ratio | -1198 |
| Inventory Turnover | -0.3 |
| Inventory/Sales | 33.3 |
| Accounts Payble/Sales | 3,092.01 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | -0.07 |
| Fixed Assets Turnover | 0.05 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.07 |
| Revenue per $ Plant | 1.21 |
| Revenue per $ Common Equity | -0.07 |
| Revenue per $ Capital Invested | 0.25 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 2879.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 226.7 |
| Research & Devlopment (R&D) as % of Revenue | 5507.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 5507.2 |
|
|  
| | |  |  | |
| |